The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Does diabetes therapy influence the risk of cancer?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“The latter assumption can no longer be considered correct, for several studies have shown metformin to be associated with a lower risk of cancer than insulin or sulfonylureas [8–10].”
BackgroundWhy we need observational studies to evaluate the effectiveness of health care
Black, N. (1996) · BMJ · doi:10.1136/bmj.312.7040.1215 · Cited by 1,598
Enhancing CD8 T-cell memory by modulating fatty acid metabolism
Pearce, E. L., Walsh, M. C., Cejas, P. J., Harms, G. M., Shen, H., Wang, L.-S., Jones, R. G., & Choi, Y. (2009) · Nature · doi:10.1038/nature08097 · Cited by 1,559 · cited 2×
“These intriguing findings indicate a shared mitochondrial nexus for metabolic and immune pathways, and imply that metformin may also have a direct influence upon immune competence [14].”
BackgroundThe influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 8×
“The three other observational analyses presented in this issue of Diabetologia were therefore commissioned to examine the safety of this insulin [ 10 , 24, 25], and the main findings will be summarised here.”
BackgroundMethodResultInfluentialSelf-citationType-II diabetes and pancreatic cancer: a meta-analysis of 36 studies
Huxley, R., Ansary-Moghaddam, A., Berrington de González, A., Barzi, F., & Woodward, M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602619 · Cited by 1,105
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis
Larsson, S. C., Orsini, N., & Wolk, A. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji375 · Cited by 1,038
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Samani, A. A., Yakar, S., LeRoith, D., & Brodt, P. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0001 · Cited by 1,005
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Frasca, F., Pandini, G., Scalia, P., Sciacca, L., Mineo, R., Costantino, A., Goldfine, I. D., Belfiore, A., & Vigneri, R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3278 · Cited by 902
Barone, B. B. (2008) · JAMA · doi:10.1001/jama.2008.824 · Cited by 881
Diabetes mellitus and risk of breast cancer: A meta‐analysis
Larsson, S. C., Mantzoros, C. S., & Wolk, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22717 · Cited by 875
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861 · cited 1×
“A study of human prostate cancer cells demonstrated a strong anti-proliferative effect of metformin [13].”
BackgroundDiabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults
Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J., & Thun, M. J. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh161 · Cited by 795
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739 · cited 3×
“Kurtzhals and colleagues used a variety of systems, including human osteosarcoma cells, to compare receptor affinities and mitogenic potencies of the insulin analogues in current clinical use, and found that insulin glargine has a six- to eightfold increase in receptor affinity and mitogenic potency compared with huma…”
BackgroundInfluentialNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
The IGF‐1 receptor in cancer biology
Baserga, R., Peruzzi, F., & Reiss, K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11487 · Cited by 642
Hemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1418-4 · Cited by 607 · cited 5×
“Insulin dose could only be estimated in terms of the number of insulin prescriptions filled, which meant that a dose–response relationship could not be examined in the same way as in the German study [23], which was based on recorded insulin doses.”
BackgroundResultInfluentialGiovannucci, E., & Michaud, D. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.050 · Cited by 543
Basal Insulin Therapy in Type 2 Diabetes
Rosenstock, J., Schwartz, S. L., Clark, C. M., Park, G. D., Donley, D. W., & Edwards, M. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.631 · Cited by 478
Jonasson, J. M., Ljung, R., Talbäck, M., Haglund, B., Gudbjörnsdòttir, S., & Steineck, G. (2009) · Diabetologia · doi:10.1007/s00125-009-1444-2 · Cited by 412
SDRN Epidemiology Group, & Colhoun, H. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1453-1 · Cited by 393
Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub3 · Cited by 366
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients
Yang, Y., Hennessy, S., & Lewis, J. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.011 · Cited by 350
Prevention of pancreatic cancer induction in hamsters by metformin
Schneider, M. B., Matsuzaki, H., Haorah, J., Ulrich, A., Standop, J., Ding, X., Adrian, T. E., & Pour, P. M. (2001) · Gastroenterology · doi:10.1053/gast.2001.23258 · Cited by 327
Zendehdel, K. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg105 · Cited by 280
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis
Singh, S. R., Ahmad, F., Lal, A., Yu, C., Bai, Z., & Bennett, H. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081041 · Cited by 243
Matveyenko, A. V., Dry, S., Cox, H. I., Moshtaghian, A., Gurlo, T., Galasso, R., Butler, A. E., & Butler, P. C. (2009) · Diabetes · doi:10.2337/db09-0058 · Cited by 242
Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies
Papanikolaou, P. N. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050873 · Cited by 229
AMP‐activated protein kinase: role in metabolism and therapeutic implications
Schimmack, G., DeFronzo, R. A., & Musi, N. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00561.x · Cited by 227
Mortality in people with Type 2 diabetes in the UK
Mulnier, H. E., Seaman, H. E., Raleigh, V. S., Soedamah‐Muthu, S. S., Colhoun, H. M., & Lawrenson, R. A. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01838.x · Cited by 212
Falck HANSEN, B., DANIELSEN, G. M., DREJER, K., SØRENSEN, A. R., WIBERG, F. C., KLEIN, H. H., & LUNDEMOSE, A. G. (1996) · Biochemical Journal · doi:10.1042/bj3150271 · Cited by 186
Weinstein, D., Simon, M., Yehezkel, E., Laron, Z., & Werner, H. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.912 · Cited by 179
Signalling through IGF-I and insulin receptors: where is the specificity?
Kim, J. J., & Accili, D. (2002) · Growth Hormone & IGF Research · doi:10.1054/ghir.2002.0265 · Cited by 163
Cryer, P. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0448-4 · Cited by 161
Metabolic syndrome, hyperinsulinemia, and cancer
Hsu, I. R., Kim, S. P., Kabir, M., & Bergman, R. N. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.867s · Cited by 158
Slieker, L. J., Brooke, G. S., DiMarchi, R. D., Flora, D. B., Green, L. K., Hoffmann, J. A., Long, H. B., Fan, L., Shields, J. E., Sundell, K. L., et al. (1997) · Diabetologia · doi:10.1007/s001250051402 · Cited by 138
Biotransformation of insulin glargine after subcutaneous injection in healthy subjects
Kuerzel, G. U., Shukla, U., Scholtz, H. E., Pretorius, S. G., Wessels, D. H., Venter, C., Potgieter, M., Lang, A. M., Koose, T., & Bernhardt, E. (2003) · Current Medical Research and Opinion · doi:10.1185/030079902125001416 · Cited by 130
Shukla, A., Grisouard, J., Ehemann, V., Hermani, A., Enzmann, H., & Mayer, D. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0240 · Cited by 130
A genetic link between type 2 diabetes and prostate cancer
Frayling, T. M., Colhoun, H. M., & Florez, J. C. (2008) · Diabetologia · doi:10.1007/s00125-008-1114-9 · Cited by 114
Rosenstock, J., Fonseca, V. A., McGill, J. B., Riddle, M. C., Hallé, J., HRAMIAK, I. M., Johnston, P., & Davis, J. L. (2009) · Diabetologia · doi:10.1007/s00125-009-1415-7 · Cited by 95
Evaluation of the Carcinogenic Potential of Insulin Glargine (LANTUS) in Rats and Mice
Stammberger, I., Bube, A., Durchfeld-Meyer, B., Donaubauer, H. H., & Troschau, G. (2002) · International Journal of Toxicology · doi:10.1080/10915810290096306 · Cited by 90
Nice insulins, pity about the evidence
Holleman, F., & Gale, E. A. M. (2007) · Diabetologia · doi:10.1007/s00125-007-0763-4 · Cited by 78
Self-citationGlargine blood biotransformation: in vitro appraisal with human insulin immunoassay
Agin, A., Jeandidier, N., Gasser, F., Grucker, D., & Sapin, R. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2006.12.002 · Cited by 72
Novel insulin analogues and its mitogenic potential
Zib, I., & Raskin, P. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00567.x · Cited by 63
Erbel, S., Reers, C., Eckstein, V., Kleeff, J. H., Büchler, M. W., Nawroth, P. P., & Ritzel, R. A. (2008) · Diabetes Care · doi:10.2337/dc07-2015 · Cited by 26
Inhaled insulin: gone with the wind?
Mathieu, C., & Gale, E. A. M. (2007) · Diabetologia · doi:10.1007/s00125-007-0875-x · Cited by 24
Self-citationBerger, M. (2000) · The Lancet · doi:10.1016/s0140-6736(05)72989-5 · Cited by 22
Cancer as an endocrine problem
Holly, J. M. P., & Perks, C. M. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.07.007 · Cited by 21
Insulin analogues and carcinoma of the breast
Ebeling, P. R. (1996) · Diabetologia · doi:10.1007/bf00400425 · Cited by 16
Cited by
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Diabetes and Cancer: A Consensus Report
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,055
Insulin Receptor Isoforms in Physiology and Disease: An Updated View
Belfiore, A., Malaguarnera, R., Vella, V., Lawrence, M. C., Sciacca, L., Frasca, F., Morrione, A., & Vigneri, R. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00073 · Cited by 375
Metadata
- Authors
- Smith, U., & Gale, E. A. M.
- Venue
- Diabetologia
- Published
- 2009-07-14
- Volume
- 52
- Issue
- 9
- Pages
- 1699-1708
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2155997251
- Cited by
- 316
- References
- 52
- FWCI
- 20.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.